Form 4: KalVista Pharmaceuticals CMO Settles RSUs and Sells Shares for Tax Obligations

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, acquired 5,000 shares of common stock through RSU vesting and subsequently sold 2,146 shares to cover tax withholding obligations.

Summary

• Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, Inc. (KALV), acquired 5,000 shares of common stock on May 22, 2025, through the vesting and settlement of Restricted Stock Units (RSUs).
• Following this acquisition, Mr. Audhya beneficially owned 115,172 shares of common stock.
• On May 23, 2025, Mr. Audhya sold 2,146 shares of common stock at a weighted average price of $11.3102 per share, with prices ranging from $11.31 to $11.36.
• This sale was explicitly stated as a 'sell to cover' transaction, intended solely to satisfy tax withholding obligations related to the RSU vesting, and was not a discretionary transaction.
• After the sale, Mr. Audhya's direct beneficial ownership of common stock stands at 113,026 shares.
• Additionally, Mr. Audhya beneficially owns 60,000 Restricted Stock Units (RSUs), with 1/16th of the total number of shares underlying the RSUs vesting on each quarterly anniversary of the Vesting Commencement Date.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine 'sell to cover' for tax purposes following RSU vesting, not a discretionary sale indicating a change in management's outlook on the company.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing details an individual insider transaction (RSU vesting and subsequent 'sell to cover' for tax purposes) and does not provide broader industry context or trends. Such transactions are routine for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: The sale of shares by the Chief Medical Officer is a non-discretionary transaction for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's operational outlook.
• Employees: The RSU vesting and 'sell to cover' transaction is a standard part of executive compensation, reflecting the company's equity incentive plans.

Next Steps

• Future vesting of the remaining 60,000 Restricted Stock Units will occur on each quarterly anniversary of the Vesting Commencement Date, with 1/16th of the total shares vesting per quarter.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Form 4, Insider Transaction, Restricted Stock Units, RSU, Sell to Cover, Chief Medical Officer, Paul K. Audhya, Stock Sale, Equity Compensation